On the day that Gilead introduced its new $94,500 hepatitis C drug, Harvoni, Gilead Vice President of Investor Relations Patrick O'Brien went into full spin mode, telling Politico (subscription required) that Harvoni is a bargain compared to Gilead's other hep C drug, the $84,000 Sovaldi. Read More
According to a recent survey from the Kaiser Family Foundation, almost every state Medicaid plan is concerned about the rising cost of specialty drugs -- specifically Sovaldi. Sovaldi is a hepatitis c drug from Gilead Sciences which costs $1,000 a pill, or $84,000 for a 12-week treatment—prices which the plans have balked at. Read More
Perhaps no company has done as much as Gilead to propel the issue of high drug prices onto center stage or to lay bare the pharmaceutical industry’s approach to pricing new drugs. Read More
Tennessee Medicaid Director Darin Gordon said today that his state has a $700… Read More
Now that the FDA has approved the Harvoni treatment from Gilead Sciencesand a $94,500 price for a 12-week regimen has been established, attention is turning toward AbbVie and the steps the big drug maker must take to win market share. Read More
How might state Medicaid programs cope with a new and equally expensive hepatitis C treatment from Gilead Sciences. Read More
The Department of Veterans Affairs, still reeling from a scandal over the negligent treatment of veterans seeking medical care that may have contributed to some deaths, has a new problem on its hands. Read More
he issue of expensive cancer drugs is hardly new, of course, but 60 Minutes aired a segment that the other night that likely helped highlight the controversy for the mass audience that watches the popular news program. Read More
Consumers keep price top of mind when they purchase prescription drugs and they’re unafraid to buy against the big labels, a new Morning Consult poll found. Read More
The 60 Minutes piece "The Cost of Cancer Drugs" aired on Oct. 5, 2014. Lesley Stahl is the correspondent. Richard Bonin, producer. Read More
Cancer treatments that genetically modify patients’ blood cells to target the disease have shown amazing results in clinical trials. Now drug companies and biotechs must overcome big hurdles to get them into hospitals, including their potential cost. Read More
60 Minutes, the most successful news program in American history… Read More